Author(s):
Carolin P, Mariappan A, Meena Kumari R
Email(s):
carolinpaul97@gmail.com
DOI:
10.52711/0974-360X.2024.00125 
Address:
Carolin P1*, Mariappan A2, Meena Kumari R3
1PG Scholar, Department of Gunapadam, National Institute of Siddha, Chennai - 47.
2Associate Professor, Department of Gunapadam, National Institute of Siddha, Chennai - 47.
3Director, National Institute of Siddha, Chennai - 47.
*Corresponding Author
Published In:
Volume - 17,
Issue - 2,
Year - 2024
ABSTRACT:
Cervical cancer become a major global burden and of course considered one of the leading causes of cancer-related deaths in women, particularly in developing countries. Viral induction of human papilloma viruses (HPV) can disturb the basic cellular mechanism of growth control. Currently medicinal plants have become the source of drug discovery in research for treating cancer. Siddha medicine is an ancient medical system of India which classifies diseases into 4448 types. In Siddha literature, Cancer is mentioned as Vippuruthinoipadalam (Carcinoma like illness), Kiranthi noi, Mega Katti, Pilavai and Putru noi (tumour). Literary evidences have a classic collection of herbal, mineral, herbo- mineral medicines for Cancer. Many anti-cancerous drugs are now in practice in Siddha medicine. Among them, Karanthai Legium (KL) a classical herbo mineral drug having anticancer potential is mentioned in Siddha Literature. The main objective of this study is to evaluate anti- cancer activity against HeLa cell using MTT assay. Present study revealed that, Karanthailegium (KL) at high as 200µg/ml showed high cytotoxicity activity as high as 72.44% against HeLa cell lines. IC50 of the tested KL against HeLa cells was calculated as104.90µg/ml. It was concluded from the result of the present study that the formulation KL possesses promising anti-cancer activity.
Cite this article:
Carolin P, Mariappan A, Meena Kumari R. In vitro Evaluation of Anticancer Activity of Karanthai Legium (Kl) – A Siddha Medicine for Cervical Carcinoma against Hela Cell Line By MTT Assay. Research Journal of Pharmacy and Technology. 2024; 17(2):807-0. doi: 10.52711/0974-360X.2024.00125
Cite(Electronic):
Carolin P, Mariappan A, Meena Kumari R. In vitro Evaluation of Anticancer Activity of Karanthai Legium (Kl) – A Siddha Medicine for Cervical Carcinoma against Hela Cell Line By MTT Assay. Research Journal of Pharmacy and Technology. 2024; 17(2):807-0. doi: 10.52711/0974-360X.2024.00125 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-2-53
REFERENCES:
1. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021; 127(16): 3029-3030.doi: 10.1002/cncr.33587.
2. World Health Organization. (2013). WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. World Health Organization.
3. International Agency for Research on Cancer (IARC). IARC Handbooks of Cancer Prevention. Volume 10. Cervix Cancer Screening. IARC Press; 2005. Accessed November 23, 2020.
4. World Health Organization. (2013). WHO guidance note: comprehensive cervical cancer prevention and control: a healthier future for girls and women. World Health Organization. https://apps.who.int/iris/handle/10665/78128
5. Priya, T. In Vitro Evaluation of Anticancer activity of Kukkilathi Choornam -A Siddha Medicine against Hela Cell Lines. World Journal of Pharmaceutical Research. 2018; 7: 376-381.doi: 10.20959/wjpr201818-13413.
6. Jeevaga Bharathi, Boga Munivar Aruliya Vaithiya Saram 700, September 2011, pg.no: 163-166.
7. Tim Mosmann. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. Journal of lmmunological Methods, 1983; 65: 55-63.doi: 10.1016/0022-1759(83)90303-4.
8. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021: 71: 209–49.doi: 10.3322/caac.21660.
9. Y. A. Ahirrao and D. A. Patil. Indigenous healthcare practices in Bhidhana district(Maharashtra). Indian Journal of Natural Products and Resources. 2010; 1(1): 85–88, doi:10.1155/2014/745439.
10. C. Muthu, M. Ayyanar, N. Raja, and S. Ignacimuthu. Medicinal plants used by traditional healers in Kancheepuram District of Tamil Nadu, India. Journal of Ethnobiology and Ethnomedicine. 2009; 2: 43. doi:10.1186/1746-4269-2-43.
11. Cheng YC, Prusoff WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22: 3099–3108. doi: 10.1016/0006-2952(73)90196-2. PMID: 4202581.
12. Neubig RR, Spedding M, Kenakin T, Christopoulos A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification International Union of Pharmacology Committee on Receptor Nomenclature and Drug classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev. 2003; 55: 597–606. doi: 10.1124/pr.55.4.4. PMID: 14657418.